SNSE
Sensei Biotherapeutics, Inc. [SNSE] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
SNSE Stock Summary
Top 10 Correlated ETFs
SNSE
Top 10 Correlated Stocks
SNSE
In the News
SNSE Financial details
Company Rating
Neutral
Market Cap
26.32M
Income
-32.87M
Revenue
2.85M
Book val./share
2.59
Cash/share
2.63
Dividend
-
Dividend %
-
Employees
28
Optionable
No
Shortable
Yes
Earnings
07 May 2024
P/E
-0.53
Forward P/E
-
PEG
0.21
P/S
-
P/B
0.28
P/C
0.38
P/FCF
-0.55
Quick Ratio
11.57
Current Ratio
11.57
Debt / Equity
0.1
LT Debt / Equity
0.06
-
-
EPS (TTM)
-1.18
EPS next Y
-
EPS next Q
-
EPS this Y
-23.27%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
7.14%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
8.98%
Inst Trans
0.88%
ROA
-46%
ROE
-44%
ROC
-0.56%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.51-1.926
52W High
-
52W Low
-
RSI
48
Rel Volume
0.32
Avg Volume
70.62K
Volume
22.78K
Perf Week
-9.18%
Perf Month
-1.99%
Perf Quarter
76.77%
Perf Half Y
42.64%
-
-
-
-
Beta
0.16
-
-
Volatility
0.02%, 0.06%
Prev Close
0.71%
Price
0.9899
Change
2.04%
SNSE Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
| Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0 | 0 | 0 | 0 | 0 | |
| Net income per share | -0.65 | -0.67 | -1.35 | -1.59 | -1.22 | |
| Operating cash flow per share | -0.29 | -0.58 | -1.09 | -1.27 | -1.15 | |
| Free cash flow per share | -0.29 | -0.62 | -1.17 | -1.28 | -1.15 | |
| Cash per share | 0.01 | 0.54 | 5.33 | 3.49 | 2.35 | |
| Book value per share | -2.34 | -1.85 | 5.29 | 3.37 | 2.32 | |
| Tangible book value per share | -2.34 | -1.85 | 5.29 | 3.37 | 2.32 | |
| Share holders equity per share | -2.34 | -1.85 | 5.29 | 3.37 | 2.32 | |
| Interest debt per share | 0.62 | 0.07 | 0.11 | 0.27 | 0.23 | |
| Market cap | 554.26M | 578.12M | 160.72M | 45.75M | 19.34M | |
| Enterprise value | 570.06M | 562.09M | 155.92M | 35.99M | 12.54M | |
| P/E ratio | -29.18 | -28.02 | -4.29 | -0.94 | -0.57 | |
| Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
| POCF ratio | -64.67 | -32.65 | -5.31 | -1.17 | -0.6 | |
| PFCF ratio | -64.27 | -30.57 | -4.98 | -1.16 | -0.6 | |
| P/B Ratio | -8.07 | -10.24 | 1.1 | 0.44 | 0.3 | |
| PTB ratio | -8.07 | -10.24 | 1.1 | 0.44 | 0.3 | |
| EV to sales | 0 | 0 | 0 | 0 | 0 | |
| Enterprise value over EBITDA | -46.11 | -31.27 | -4.33 | -0.72 | -0.34 | |
| EV to operating cash flow | -66.51 | -31.75 | -5.15 | -0.92 | -0.39 | |
| EV to free cash flow | -66.1 | -29.72 | -4.83 | -0.91 | -0.39 | |
| Earnings yield | -0.03 | -0.04 | -0.23 | -1.07 | -1.76 | |
| Free cash flow yield | -0.02 | -0.03 | -0.2 | -0.86 | -1.66 | |
| Debt to equity | -0.23 | -0.01 | 0.02 | 0.08 | 0.1 | |
| Debt to assets | 13.19 | 0.03 | 0.02 | 0.07 | 0.08 | |
| Net debt to EBITDA | -1.28 | 0.89 | 0.13 | 0.19 | 0.19 | |
| Current ratio | 0.02 | 4.16 | 30.38 | 11.98 | 11.92 | |
| Interest coverage | -5.51 | -11.52 | -55.94 | -229.17 | -257.39 | |
| Income quality | 0.51 | 0.88 | 0.82 | 0.8 | 0.94 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0.01 | 0.07 | 0.07 | 0.01 | 0.01 | |
| Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | -0.73 | -5.77 | -2.96 | -0.24 | -0.32 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 5.84 | 5.29 | 12.68 | 10.98 | 7.98 | |
| ROIC | 0.27 | 0.36 | -0.25 | -0.42 | -0.5 | |
| Return on tangible assets | -15.61 | -0.96 | -0.24 | -0.41 | -0.46 | |
| Graham Net | -2.37 | -2 | 5.09 | 3 | 2.01 | |
| Working capital | -21.21M | 15.25M | 143.65M | 99.52M | 61.61M | |
| Tangible asset value | -68.66M | -56.44M | 146.51M | 103.41M | 64.9M | |
| Net current asset value | -69.38M | -57.8M | 141.83M | 93.62M | 57.77M | |
| Invested capital | -0.23 | -0.01 | 0.02 | 0.08 | 0.1 | |
| Average receivables | 0 | 0 | 0 | 0 | 0 | |
| Average payables | 2.28M | 3.67M | 3.17M | 3.46M | 3.08M | |
| Average inventory | 0 | 0 | 0 | 0 | 0 | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 17.26K | 6.78K | 1.31K | 903.01 | 1.08K | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 0.02 | 0.05 | 0.28 | 0.4 | 0.34 | |
| Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
| ROE | 0.28 | 0.37 | -0.26 | -0.47 | -0.53 | |
| Capex per share | 0 | -0.04 | -0.07 | -0.01 | -0.01 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
| Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0 | 0 | 0 | 0 | 0.11 | |
| Net income per share | -0.4 | -0.29 | -0.31 | -0.28 | -0.3 | |
| Operating cash flow per share | -0.31 | -0.38 | -0.31 | -0.18 | -0.25 | |
| Free cash flow per share | -0.31 | -0.39 | -0.31 | -0.18 | -0.25 | |
| Cash per share | 3.48 | 3.09 | 2.58 | 2.82 | 2.63 | |
| Book value per share | 3.36 | 3.07 | 2.6 | 2.78 | 2.59 | |
| Tangible book value per share | 3.36 | 3.07 | 2.6 | 2.78 | 2.59 | |
| Share holders equity per share | 3.36 | 3.07 | 2.6 | 2.78 | 2.59 | |
| Interest debt per share | 0.25 | 0.25 | 0.24 | 0.27 | 0.25 | |
| Market cap | 45.81M | 46.3M | 34.78M | 20.41M | 17.32M | |
| Enterprise value | 36.04M | 45.94M | 31.82M | 15.84M | 10.52M | |
| P/E ratio | -0.92 | -1.29 | -0.93 | -0.72 | -0.58 | |
| Price to sales ratio | 0 | 0 | 0 | 0 | 6.09 | |
| POCF ratio | -4.78 | -3.95 | -3.68 | -4.38 | -2.81 | |
| PFCF ratio | -4.75 | -3.89 | -3.66 | -4.38 | -2.81 | |
| P/B Ratio | 0.44 | 0.49 | 0.44 | 0.29 | 0.27 | |
| PTB ratio | 0.44 | 0.49 | 0.44 | 0.29 | 0.27 | |
| EV to sales | 0 | 0 | 0 | 0 | 3.7 | |
| Enterprise value over EBITDA | -2.53 | -4.17 | -3.61 | -2.05 | -1.31 | |
| EV to operating cash flow | -3.76 | -3.91 | -3.36 | -3.4 | -1.71 | |
| EV to free cash flow | -3.74 | -3.86 | -3.35 | -3.4 | -1.71 | |
| Earnings yield | -0.27 | -0.19 | -0.27 | -0.35 | -0.43 | |
| Free cash flow yield | -0.21 | -0.26 | -0.27 | -0.23 | -0.36 | |
| Debt to equity | 0.08 | 0.08 | 0.09 | 0.1 | 0.1 | |
| Debt to assets | 0.07 | 0.07 | 0.08 | 0.08 | 0.08 | |
| Net debt to EBITDA | 0.68 | 0.03 | 0.34 | 0.59 | 0.85 | |
| Current ratio | 11.98 | 13 | 15.13 | 11.57 | 11.92 | |
| Interest coverage | 63.34 | -262.1 | -267.82 | -234.45 | -262.65 | |
| Income quality | 0.78 | 1.15 | 1.01 | 0.65 | 0.83 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 1.28 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 1.58 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0.01 | 0.01 | 0 | 0 | 0 | |
| Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | -0.2 | -0.42 | -0.09 | 0 | 0 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0.39 | |
| Graham number | 5.53 | 4.48 | 4.24 | 4.18 | 4.16 | |
| ROIC | -0.11 | -0.09 | -0.11 | -0.09 | -0.13 | |
| Return on tangible assets | -0.11 | -0.08 | -0.1 | -0.09 | -0.1 | |
| Graham Net | 3 | 2.67 | 2.24 | 2.4 | 2.25 | |
| Working capital | 99.52M | 91.03M | 75.71M | 65.79M | 61.61M | |
| Tangible asset value | 103.41M | 94.85M | 79.2M | 71M | 64.9M | |
| Net current asset value | 93.62M | 85.53M | 70.69M | 61.36M | 57.77M | |
| Invested capital | 0.08 | 0.08 | 0.09 | 0.1 | 0.1 | |
| Average receivables | 0 | 0 | 0 | 0 | 0 | |
| Average payables | 4.57M | 4.59M | 3.52M | 2.53M | 2.21M | |
| Average inventory | 0 | 0 | 0 | 0 | 0 | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 858.36 | 889.62 | 426.9 | 539.41 | 1.13K | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 0.1 | 0.1 | 0.21 | 0.17 | 0.08 | |
| Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
| ROE | -0.12 | -0.09 | -0.12 | -0.1 | -0.11 | |
| Capex per share | 0 | 0 | 0 | 0 | 0 |
SNSE Frequently Asked Questions
What is Sensei Biotherapeutics, Inc. stock symbol ?
Sensei Biotherapeutics, Inc. is a US stock , located in Rockville of Md and trading under the symbol SNSE
What is Sensei Biotherapeutics, Inc. stock quote today ?
Sensei Biotherapeutics, Inc. stock price is $0.9899 today.
Is Sensei Biotherapeutics, Inc. stock public?
Yes, Sensei Biotherapeutics, Inc. is a publicly traded company.
Company Profile
- Volume Average 70.62K
- Market Capitalization 26.32M
- Employee 28
- CEO Mr. John K. Celebi M.B.A.
- Headquarters Rockville,MD,US
- IPO Date 2021-02-04
-
Website
https://www.senseibio.com 
Sensei Biotherapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of immunotherapies with an initial focus on treatments for cancer. It develops proprietary ImmunoPhage platform, an immunotherapy approach that is designed to utilize bacteriophage to induce a focused and coordinated innate and adaptive immune response; and Tumor Microenvironment Activated Biologics, a platform designed to unleash the anti-tumor potential of T-cells, as well as human monoclonal antibodies that are selectively active in the tumor microenvironment and target immune checkpoints or other critical immune pathways. The company also develops SNS-101, a monoclonal antibody for the treatment of cancer; and SNS-401-NG, an ImmunoPhage vaccine targeting multiple tumor antigens. It has a collaboration with The University of Washington to research and develop Merkel cell carcinoma vaccine. The company was formerly known as Panacea Pharmaceuticals, Inc. Sensei Biotherapeutics, Inc. was incorporated in 1999 and is headquartered in Rockville, Maryland.
